Watchlist
AstraZeneca Plc (AZN.L) Announced that the US Food and Drug Administration (FDA) has approved Farxiga (dapagliflozin) to reduce the risk of hospitalisation for heart failure (hHF) in adults with type-2 diabetes (T2D) and established cardiovascular disease (CVD) or multiple cardiovascular (CV) risk factors. The approval is based on results from the landmark DECLARE-TIMI 58 CV outcomes trial (CVOT), the largest sodiumglucose cotransporter 2 (SGLT2) inhibitor CVOT conducted to date to evaluate T2D patients with multiple CV risk factors or established CV disease.
info
Login or register to post comments